AI Article Synopsis
- - The 2020 Nobel Prize in Medicine was awarded to Drs. Harvey Alter, Michael Houghton, and Charles Rice for their groundbreaking work on the hepatitis C virus, leading to lifesaving therapies.
- - The tribute discusses the historical significance of the laureates' discoveries and includes insights from a forum held by the American Association for the Study of Liver Diseases, where the laureates shared advice for emerging scientists.
- - Colleagues and peers in the research community also contribute personal reflections and stories about their experiences working with the Nobel laureates.
Article Abstract
The 2020 Nobel Prize in Medicine or Physiology was awarded to Drs. Harvey Alter, Michael Houghton, and Charles Rice for their contributions to the discovery and characterization of the hepatitis C virus (HCV). Their achievements represent a remarkable triumph of biomedical science which allowed the development of curative therapy for HCV, that will save countless lives. This tribute provides a historical perspective of the laureates' seminal work leading to the discovery of the HCV and a synopsis of a forum hosted by the American Association for the Study of Liver Diseases to honor the laureates in which they offered their perspectives, advice for young investigators and what's left to accomplish in the field. Finally, others in the research community who have worked closely with one or more of the laureates, share some of their personal reflections and anecdotes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577909 | PMC |
| http://dx.doi.org/10.1002/hep.31830 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A prospective cohort of treatment-seeking patients with problematic use of prescription narcotic drugs: study protocol and baseline characteristics.
BMC Psychiatry
December 2024
The Stockholm Centre for Dependency Disorders, Stockholm Health Care Services, Region Stockholm, Friskvårdsvägen 4, Stockholm, 112 81, Sweden.
Background: There is limited knowledge on long-term outcomes of tapering treatment for individuals with problematic use of prescription narcotics, including opioids and benzodiazepines. The overall aim of the study is to investigate clinical trajectories and treatment outcomes of patients seeking treatment in addiction care.
Methods: This paper presents the study protocol and baseline characteristics of a cohort of patients seeking treatment for problematic use of prescription narcotic drugs at specialized outpatient addiction services.
Exploring the genetics of airflow limitation in lung function across the lifespan - a polygenic risk score study.
EClinicalMedicine
September 2024
Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Sjukhusbacken 10, 118 83, Stockholm, Sweden.
Article Synopsis
- Chronic obstructive pulmonary disease (COPD) can be influenced by genetic factors and may stem from reduced lung growth during childhood, leading to lower lung function throughout life.
- A polygenic risk score (PRS) was calculated using data from a large genome-wide association study and tested for its correlation with lung function in individuals aged 4-50 from multiple research cohorts.
- Results indicated that higher PRS scores were associated with significantly lower lung function, measured by key indicators, starting from childhood and continuing into adulthood, regardless of smoking, sex, or asthma diagnosis.
Emerging Gene-editing nano-therapeutics for Cancer.
Heliyon
November 2024
Amrita School of Nanosciences and Molecular Medicine, Amrita Vishwavidyapeetham (University), Ponekkara P.O., Kochi, India.
Remarkable progress has been made in the field of genome engineering after the discovery of CRISPR/Cas9 in 2012 by Jennifer Doudna and Emmanuelle Charpentier. Compared to any other gene-editing tools, CRISPR/Cas9 attracted the attention of the scientific community because of its simplicity, specificity, and multiplex editing possibilities for which the inventors were awarded the Nobel prize for chemistry in 2020. CRISPR/Cas9 allows targeted alteration of the genomic sequence, gene regulation, and epigenetic modifications using an RNA-guided site-specific endonuclease.
View Article and Find Full Text PDFMaking gene editing accessible in resource limited environments: recommendations to guide a first-time user.
Front Genome Ed
September 2024
Bioengineering and Integrated Genomics Group, Future Production Chemicals Cluster, Council for Scientific and Industrial Research, Pretoria, South Africa.
Article Synopsis
- The CRISPR-Cas9 system has revolutionized genome engineering due to its ease of use, leading to a Nobel Prize win in Chemistry in 2020 for its developers.
- *Recent advancements in gene therapy, particularly in the Global North, showcase its potential benefits in treating diseases like sickle cell anaemia and improving transplant options.
- *However, challenges in the Global South, such as funding limitations and a shortage of skilled professionals, hinder the adoption of this technology, emphasizing the need for cost-effective methods and increased accessibility.*
Advanced Hybrid Closed-Loop Therapy Compared With Standard Insulin Therapy Intrapartum and Early Postpartum in Women With Type 1 Diabetes: A Secondary Observational Analysis From the CRISTAL Randomized Controlled Trial.
Diabetes Care
November 2024
Clinical and Experimental Endocrinology, KU Leuven, Leuven, Belgium.
Objective: To determine efficacy and safety of intrapartum and early postpartum advanced hybrid closed-loop (AHCL) therapy compared with standard insulin therapy in pregnant women with type 1 diabetes (T1D).
Research Design And Methods: CRISTAL was a double-arm, open-label, randomized controlled trial performed in Belgium and the Netherlands that assigned 95 pregnant participants with T1D 1:1 to a MiniMed 780G AHCL system (n = 46) or standard insulin therapy (n = 49). This prespecified, secondary observational analysis focused on differences in glycemic control and safety outcomes between participants from the original AHCL group who continued AHCL intrapartum (n = 27) and/or early postpartum (n = 37, until hospital discharge) and those from the original standard insulin therapy group using standard insulin therapy intrapartum (n = 45) and/or early postpartum (n = 34).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!